Church & Dwight Canada has been the manufacturer of GRAVOLTM for over 60 years. GravolTM products are proudly researched, developed, and manufactured by a staff of over 150 people at Church & Dwight’s facility in Montreal, Canada.*
In Canada, we follow strict health and safety guidelines, as per the Food and Drug Act of Health Canada, which are designed to protect our consumers and our employees. At Church & Dwight, under the guidance of our Director of Quality and Regulatory Affairs, Elaine Moreau (M.Sc. University of Montreal), we are proud to meet these high standards of quality. Our plant in Montreal manufactures 72 million tablets of various GravolTM products per year. Because our site operates according to good manufacturing practices (GMPs) and must comply with Health Canada regulations, each and every one of these products must meet rigorous standards. This means that all manufacturing ingredients and packaging components used in the production of GRAVOLTM products must be tested for quality control. Our manufacturing recipe to produce GravolTM 50 mg Filmkote tablets contains 57 pages and 45 different instructions designed to ensure adherence to consistent manufacturing procedures and quality specifications. At Church & Dwight, we are proud to operate with conviction, accountability and transparency. You can be sure that your Church & Dwight product is homegrown and meets the highest standards of quality.
A team of scientists and technicians led by our R&D Product Development Manager, Alain Desjardins are constantly researching and developing new products. The pharmaceutical drugs are produced in Montreal and are readily available in Canada with limited availability through export in select countries throughout the world.
*GravolTM Natural Source Ginger Lozenges are manufactured in Germany.